Cover image of MPS II guidelines


Life Saving Drugs Program – Mucopolysaccharidosis type II (MPS II) – Guidelines

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Publication date: 
March 2018
Publication type: 
Intended audience: 
Health sector

These guidelines include:

  • General information about the Life Saving Drugs Program (LSDP)
  • Treatment of mucopolysaccharidosis type II (MPS II) through the LSDP
  • Drugs currently available for the treatment of MPS II through the LSDP
  • Dosage
  • General, initial and ongoing eligibility requirements
  • LSDP funding conditions
  • Exclusion criteria.